Pani, Luca

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 2,803

Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 651

The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review

Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs

Schizophrenia research and treatmentPituitary Gland Disorders and Treatments

Cited by 350

A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials

Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry

Treatment of Major DepressionDelphi Technique in Research

Cited by 214

Identification and validation of biomarkers for autism spectrum disorders

Loth, E., Spooren, W., Ham, L. M., Isaac, M. B., Auriche-Benichou, C., Banaschewski, T., Baron-Cohen, S., Broich, K., Bölte, S., Bourgeron, T., et al. (2016) · Nature Reviews Drug Discovery

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 140

REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial

Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

The endless frontier? The recent increase of R&D productivity in pharmaceuticals

Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020) · Journal of Translational Medicine

Pharmaceutical Economics and PolicyFirm Innovation and Growth

Cited by 77

Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors

Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 31

Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder

Guidetti, C., Serra, G., Pani, L., Pappagallo, M., Maglio, G., Martin, S. D., Mattarei, A., Folli, F., Manfredi, P. L., & Fava, M. (2023) · The Primary Care Companion For CNS Disorders

Treatment of Major DepressionSchizophrenia research and treatment

Cited by 4

A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire

Guidetti, C., Fava, M., Pani, L., Pappagallo, M., Serra, G., DeMartin, S., Mattarei, A., & Manfredi, P. L. (2022) · CNS Spectrums

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 3